Vivus, Inc. (VVUSQ)
| Market Cap | 2.10M |
| Revenue (ttm) | 73.25M |
| Net Income (ttm) | -28.77M |
| Shares Out | 10.65M |
| EPS (ttm) | -2.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Dec 11, 2021 |
| Last Price | $0.1174 |
| Previous Close | $0.1200 |
| Change ($) | -0.0026 |
| Change (%) | -2.17% |
| Day's Open | 0.1156 |
| Day's Range | 0.1110 - 0.1225 |
| Day's Volume | 103,035 |
| 52-Week Range | 0.07 - 3.57 |
News
CAMPBELL, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Co...
CAMPBELL, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan o...
CAMPBELL, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-co...
CAMPBELL, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its co...
VIVUS, Inc's (VVUS) CEO John Amos on Q1 2020 Results - Earnings Call Transcript
CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH ...
VIVUS Finding Support After Launch Of Its Remote Health Platform
CAMPBELL, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced regist...
Vivus (NASDAQ: VVUS) shares were trading lower on Wednesday, after the company priced its 7.22 million share common stock offering at $1.60 per share.
CAMPBELL, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements wi...
Shares of biopharma company VIVUS, Inc. (NASDAQ: VVUS) are skyrocketing following an announcement concerning launch plans for telemedicine services.
Vivus Inc. (NASDAQ: VVUS) shares absolutely exploded on Tuesday after the company announced that it was accelerating the launch of the telemedicine and remote monitoring modules of the Vivus H...
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased...
VIVUS, Inc. (VVUS) CEO John Amos on Q4 2019 Results - Earnings Call Transcript
- Company to host conference call today at 4:30pm ET -
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need-
- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia -
Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S.
CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has ap...
-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia-
CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors ...
-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoin...
Shares of Vivus Inc. rose 9% in morning trading after the drugmaker said its weight-loss drug Qsymia can reduce binging frequency for patients with binge-eating disorder or bulimia nervosa.
-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo-
VIVUS, Inc. (VVUS) CEO John Amos on Q3 2019 Results - Earnings Call Transcript
CAMPBELL, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resig...
CAMPBELL, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos, Chief Executive Officer, will par...
CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denm...
CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,...
-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea-
-Data published in Surgery for Obesity and Related Diseases also show that patients in the Qsymia group lost more than twice as much weight during preoperative treatment compared with control ...
VIVUS, Inc. (VVUS) CEO John Amos on Q2 2019 Results - Earnings Call Transcript
VIVUS, Inc. (VVUS) CEO John Amos on Q1 2019 Results - Earnings Call Transcript
About VVUSQ
VIVUS operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to tre... [Read more...]
| Industry Biotechnology | IPO Date Apr 6, 1994 |
| CEO John Amos | Employees 59 |
| Stock Exchange OTCMKTS | Ticker Symbol VVUSQ |
Financial Performance
In 2019, Vivus's revenue was $69.76 million, an increase of 7.22% compared to the previous year's $65.06 million. Losses were -$31.50 million, -14.74% less than in 2018.